SIGA · SIGA Technologies, Inc.

SIGA Technologies reported financial results for the first quarter ended March 31, 2026, with total revenues of $6.2 million, down from $7.0 million in the same period last year. The decline was primarily driven by lower product sales and supportive services, which fell to $3.5 million from $5.8 million, partially offset by higher research and development revenues of $2.7 million (up from $1.2 million). Operating loss widened to $5.3 million from $2.3 million, reflecting increased cost of sales and supportive services ($2.9 million vs. $0.2 million) and higher R&D expenses ($3.9 million vs. $3.5 million). Net loss was $3.5 million ($0.05 per share) compared to $0.4 million ($0.01 per share) in Q1 2025.

Management highlighted key upcoming deliveries: approximately $13 million of oral TPOXX to an Asia Pacific customer in Q2 2026 under a multi-year contract, and $26 million of IV TPOXX to the U.S. Government Strategic National Stockpile by end of Q3 2026 under the 19C BARDA contract. CEO Diem Nguyen stated, "Consistent with our long-term strategy, we expect to deliver more than $35 million of oral and IV TPOXX to a combination of the U.S. Government and an international customer across the second and third quarters of 2026." The company also announced an exclusive license agreement with Hikma MENA FZE for oral TPOXX in the Middle East and North Africa region. A special cash dividend of $0.60 per share was declared on March 26, 2026, and paid on April 23, 2026. The balance sheet remains strong with $145.6 million in cash and cash equivalents as of March 31, 2026.